Trastuzumab Active Not Recruiting Phase 2 Trials for Breast Cancer Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00470704Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
NCT02132949A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
NCT02339532Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
NCT03161353Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
NCT01745965A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
NCT01853748T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
NCT00295893Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
NCT02909751Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
NCT01937117Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
NCT00999804Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
NCT00796978Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
NCT01796197Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
NCT01625429Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer